Insider trade

Cytokinetics (CYTK): CEO sold ~$300K

Robert I Blum, CEO at Cytokinetics, sold ~$300K of Cytokinetics shares.

~$300K
Approx. value · 5,000 sh @ $60.03
363K
Holds after · shares reported
Traded
Oct 16, 2025
Filed
Oct 16, 2025

What stands out in this filing

  • The sale was 1.4% of the shares this insider held before it; the filing reports 363,108 shares afterwards.
  • 5,000 shares at an average of $60.03 each, as reported on the form.
  • Filing box checked: sold under a Rule 10b5-1 plan.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 19, 2025InsiderOfficer sold ~$77K of CYTK shares in the open market
  2. Sep 2, 2025Insider · 3 peopleInsiders: 3 sales (~$686K)
  3. Sep 9, 2025InsiderOfficer sold ~$103K of CYTK shares in the open market
  4. Sep 15, 2025InsiderCEO sold ~$249K of CYTK shares in the open market
  5. Sep 16, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  6. Sep 23, 2025InsiderOfficer sold ~$99K of CYTK shares in the open market
  7. Sep 30, 2025InsiderDirector sold ~$369K of CYTK shares in the open market
  8. Oct 6, 2025InsiderDirector sold ~$405K of CYTK shares in the open market
  9. Oct 7, 2025InsiderOfficer sold ~$121K of CYTK shares in the open market
  10. Oct 9, 2025CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
  11. Oct 16, 2025 · this disclosureInsiderCEO sold ~$300K of CYTK shares in the open market

What came next

  1. Oct 21, 2025InsiderOfficer sold ~$123K of CYTK shares in the open market
  2. Oct 27, 2025InsiderDirector sold ~$257K of CYTK shares in the open market
  3. Oct 30, 2025InsiderCEO sold ~$314K of CYTK shares in the open market
  4. Nov 4, 2025InsiderOfficer sold ~$137K of CYTK shares in the open market
  5. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
  6. Nov 11, 2025InsiderDirector sold ~$337K of CYTK shares in the open market
  7. Nov 13, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 13, 2025, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Jeffrey J. Hessekiel, pursuant to which Mr. Hessekiel has agreed to serve as the Company’s Executive Vice President, Chief Legal and Administrative Officer, effective as of November 14, 2025 (the “Start Date”).”
  8. Nov 18, 2025InsiderOfficer sold ~$146K of CYTK shares in the open market
  9. Nov 19, 2025InsiderDirector sold ~$324K of CYTK shares in the open market
  10. Dec 1, 2025Insider · 2 peopleInsiders: 2 sales (~$2.0M)
  11. Dec 2, 2025Insider · 2 peopleInsiders: 2 sales (~$700K)
  12. Dec 5, 2025InsiderOfficer sold ~$3.46M of CYTK shares in the open market
  13. Dec 8, 2025InsiderOfficer sold ~$69K of CYTK shares in the open market
  14. Dec 16, 2025InsiderOfficer sold ~$135K of CYTK shares in the open market
  15. Dec 22, 2025InsiderDirector sold ~$1.32M of CYTK shares in the open market
  16. Dec 29, 2025InsiderOfficer sold ~$113K of CYTK shares in the open market
  17. Jan 2, 2026Insider · 1 personInsiders: 2 sales (~$113K)
  18. Jan 5, 2026InsiderOfficer sold ~$904K of CYTK shares in the open market
  19. Feb 2, 2026InsiderOfficer sold ~$55K of CYTK shares in the open market
  20. Feb 5, 2026InsiderOfficer sold ~$929K of CYTK shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytokinetics

For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.

Other recent filings by Robert I Blum, President & CEO

The full history of Robert I Blum, President & CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Cytokinetics (CYTK) insider traded, and how much?

Robert I Blum, CEO at Cytokinetics, sold ~$300K of Cytokinetics shares. 5,000 shares at $60.03.

When did it happen, and when was it made public?

Traded: Oct 16, 2025. Filed: Oct 16, 2025.

What stands out in this filing?

The sale was 1.4% of the shares this insider held before it; the filing reports 363,108 shares afterwards. 5,000 shares at an average of $60.03 each, as reported on the form. Filing box checked: sold under a Rule 10b5-1 plan.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Cytokinetics recently?

For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.

Does this mean CYTK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Cytokinetics

Everything OQRO holds on this company is on its CYTK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data